NSI-189 Archives | Be Korea-savvy

Home / Posts tagged NSI-189

Neuralstem Announces NSI-189 Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Angelman Syndrome

GERMANTOWN, Md., Aug. 9 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to NSI-189 for the treatment of Angelman syndrome. “Angelman Syndrome is a rare disease [...]

Neuralstem Presents Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting

GERMANTOWN, Md., Dec. 5 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that additional safety, efficacy and tolerability data from its exploratory Phase 2 clinical trial examining the efficacy of NSI-189 at 40 mg once daily (QD) and 40 mg twice daily (BID) compared to [...]

Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting

GERMANTOWN, Md., Nov. 16 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that data from the Company’s Phase 2 study of NSI-189 in patients with major depressive disorder will be presented at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting, which is being held [...]

Neuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular Physiology

GERMANTOWN, Md., Feb. 28 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announced the recent publication of preclinical data on NSI-189 in Journal of Cellular Physiology. The study demonstrated that NSI-189 improved behavioral function recovery and enhanced hippocampal synaptic [...]

Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder

GERMANTOWN, Md., Feb. 16 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced completion of subject enrollment in its Phase 2 clinical trial of NSI-189 for the treatment of major depressive disorder (MDD). NSI-189 is a new [...]